Bay Area cryballoon ablation startup C2 Therapeutics just raised $11.6 million, according to a regulatory filing.
The company’s Coldplay Focal Cryoballoon Ablation System is meant to treat Barrett’s Esophagus – a fairly asymptomatic condition in which the tissue lining the esophagus gets replaced by a different kind of tissue – the sort that is found in the intestinal system. It’s most seen in people with acid reflux issues. Without treatment, a portion of these folks are at risk for a rare kind of cancer called esophageal adenocarcinoma.
C2’s device is administered through a scope, and expands as a balloon catheter that’s simultaneously inflated and cooled by an inert refrigerant delivered through a small, handheld unit, the company said. The balloon then conforms to the shape of the esophagus.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The company’s raised about $10 million since 2007, according to regulatory filings.
[Photo from Flickr user zzzack]
